Additional studies in CLL demonstrated that inhibiting UGCG sensitizes cells to various drugs such as fludarabine, chlorambucil, and inhibitor of BCL-2 (ABT-737) [6, 13, 14]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.